Navigation Links
Avastin May Help Boost Survival With Aggressive Cervical Cancer: Study
Date:2/8/2013

FRIDAY, Feb. 8 (HealthDay News) -- The cancer drug Avastin may extend the lives of patients with aggressive cervical cancer, a new study finds.

The findings might change the way these patients are treated and improve outcomes for women "who have previously had very limited treatment options," study lead researcher Dr. Krishnansu Tewari, said in a news release from the U.S. National Cancer Institute (NCI).

The research was sponsored by the NCI and received support from Genentech Inc., which makes Avastin.

The study included 452 women with recurrent, advanced or persistent cervical cancer that was not curable with standard chemotherapy. Patients who received Avastin with their chemotherapy lived an average of 17 months, compared with just over 13 months for those treated with chemotherapy alone, the investigators found.

The patients who received Avastin were given a dose of 15 milligrams per kilogram of body weight, which was administered in the vein with their chemotherapy treatment. The dose was given one day every three weeks until the patient's cancer progressed or levels of the drug in the body became too high.

Patients who received Avastin did have more side effects than those who didn't take the drug, the researchers noted, and the side effects were consistent with those known to be associated with Avastin -- events such as bleeding, clotting and gastrointestinal issues.

Avastin also comes with a hefty price tag, about $5,000 per month.

Still, the increase in survival seen with Avastin "is welcome news as progress has been very difficult against this cancer," Dr. Jeff Abrams, clinical director of NCI's Division of Cancer Treatment and Diagnosis, said in the news release.

Another expert not connected to the study agreed.

Dr. Elizabeth Poynor, a gynecologic oncologist and pelvic surgeon at Lenox Hill Hospital in New York City, noted that women with advanced cervical cancers that prove resistant to standard treatments "have traditionally been a very difficult group to treat effectively with regimens available." She said the new study "provides new opportunities to develop and further refine treatments for this group."

The data has been submitted for presentation in June at the annual meeting of the American Society of Clinical Oncology. Research that has not undergone peer review is typically considered preliminary until such review is completed.

More than 12,000 women will be diagnosed with cervical cancer in the United States in 2013 and over 4,000 women will die of the disease.

More information

The American Academy of Family Physicians has more about cervical cancer.

-- Robert Preidt

SOURCES: Elizabeth Poynor, M.D., gynecologic oncologist and pelvic surgeon, Lenox Hill Hospital, New York City; U.S. National Cancer Institute, news release, Feb. 7, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. FDA Issues Another Warning on Fake Version of Cancer Drug Avastin
2. Avastin Shows No Benefit for Earlier Colon Cancer: Study
3. Avastin Wont Extend Breast Cancer Survival: Study
4. Interpreting the Avastin-Lucentis study for persons with macular degeneration
5. Avastin No Benefit to Older Lung Cancer Patients: Study
6. More Fake Avastin Found in U.S., FDA Says
7. A Good Mood May Boost Seniors Brain Power
8. Living Near Equator May Boost Your Risk for Allergy, Asthma
9. Personalized plans to address barriers to HIV drug adherence boost chances of successful therapy
10. Fried Foods May Boost Prostate Cancer Risk, Study Says
11. Plastic Surgery Practice Gets Boost from Lower Eyelid Surgery Webinar
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Avastin May Help Boost Survival With Aggressive Cervical Cancer: Study
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... Mirroring360 Pro . This new addition to the Mirroring360 product family combines ... and business. , Mirroring360 Pro enables educators, business professionals and individuals to stream ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report ... score performance for the 2015-16 school year across Wisconsin’s public schools, charter schools, ... highlights important patterns in student test score performance, the report’s limited analyses fail ...
(Date:4/25/2017)... ... April 25, 2017 , ... As Spring ... birth defects research related to Zika virus during pregnancy, as well as other ... this important science. , The Teratology Society is an international ...
(Date:4/25/2017)... ... , ... Emergency Physician and Distinguished Professor of Emergency Medicine Bentley Bobrow will ... set to publish in summer 2017. , Dr. Bobrow, MD, FACEP, FAHA, is ... of Medicine. He also serves as Medical Director for the Bureau of Emergency Medical ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017 Global Prostate Cancer ... on the prostate cancer therapeutics market analyzes the ... Increasing prevalence of prostate cancer, launch of promising ... development of new drugs & therapeutic biological products, ... due to lesser side effects are some of ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
(Date:4/19/2017)... -- Companion animal vaccines are ... such as canine, avian and feline. ... as Attenuated Live Vaccines, Conjugate Vaccines, Inactivated Vaccines, ... Vaccines. Attenuated live vaccines are derived from disease-causing ... been weakend under laboratory conditions. Conjugate vaccines are ...
Breaking Medicine Technology: